Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Accurate prediction of repeat prostate biopsy outcomes by a mitochondrial DNA deletion assay

Prostate Cancer and Prostatic Diseases volume 13, pages 126–131 (2010)Cite this article

Subjects

A Corrigendum to this article was published on 12 November 2013

Abstract

Several cancers are characterized by large-scale mtDNA deletions. We previously provided evidence that one of these deletions has potential utility in resolving false from true-negative prostate needle biopsies. This study was to assess the clinical value of this deletion in predicting re-biopsy outcomes. We used a quantitative polymerase chain reaction assay to measure the levels of the deletion in individual negative needle biopsies from 101 patients who had a repeat biopsy within a year with known outcomes. Using an empirically established cycle threshold (Ct) cutoff of 31, and the lowest Ct for each patient as diagnostic of prostate cancer, as well as the histopathologic diagnosis on second biopsy, we calculated the clinical performance of the deletion. The Ct cutoff at 31 gave a sensitivity and specificity of 84 and 54%, respectively, with the area under a receiver-operating characteristics curve of 0.749. The negative predictive value was 91%. The assay was able to predict the presence of a missed tumor in 17 out of 20 men a year before diagnosis. This ancillary test appears to identify men who do not require a repeat biopsy with a high degree of certainty. The results suggest that the majority of men with atypical small acinar proliferation have a concurrent missed tumor and therefore require close monitoring for early detection.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001; 412: 822–826.

    Article  CAS  Google Scholar 

  2. Satoh A, Matsumoto K, Nakamura S . Is interval from an initial biopsy a significant predictor of prostate cancer at repeat biopsies? Int J Urol 2006; 13: 224–227.

    Article  Google Scholar 

  3. Eggener SE, Roehl KA, Catalona WJ . Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6–4.0 ng/ml and an initially negative biopsy. J Urol 2005; 174: 500–504.

    Article  Google Scholar 

  4. Singh H, Canto EI, Shariat SF, Kadmon D, Miles BJ, Wheeler TM et al. Predictors of prostate cancer after initial negative systematic 12 core biopsy. J Urol 2004; 171: 1850–1854.

    Article  Google Scholar 

  5. Hong YM, Lai FC, Chon CH, McNeal JE, Presti Jr JC . Impact of prior biopsy scheme on pathologic features of cancers detected on repeat biopsies. Urol Oncol 2004; 22: 7–10.

    Article  Google Scholar 

  6. Epstein JI, Herawi M . Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J Urol 2006; 175 (3 Pt 1): 820–834.

    Article  Google Scholar 

  7. Brausi M, Castagnetti G, Dotti A, De Luca G, Olmi R, Cesinaro AM . Immediate radical prostatectomy in patients with atypical small acinar proliferation. Over treatment? J Urol 2004; 172: 906–908 discussion 908-909.

    Article  Google Scholar 

  8. Fowler Jr FJ, Barry MJ, Walker-Corkery B, Caubet JF, Bates DW, Lee JM et al. The impact of a suspicious prostate biopsy on patients psychological, socio-behavioral, and medical care outcomes. J Gen Intern Med 2006; 21: 715–721.

    Article  Google Scholar 

  9. Maki J, Robinson K, Reguly B, Alexander J, Wittock R, Aguirre A et al. Mitochondrial genome deletion aids in the identification of false- and true-negative prostate needle core biopsy specimens. Am J Clin Pathol 2008; 129: 57–66.

    Article  CAS  Google Scholar 

  10. Bostwick DG, Meiers I . Atypical small acinar proliferation in the prostate: clinical significance in 2006. Arch Pathol Lab Med 2006; 130: 952–957.

    PubMed  Google Scholar 

  11. Dhir R, Vietmeier B, Arlotti J, Acquafondata M, Landsittel D, Masterson R et al. Early identification of individuals with prostate cancer in negative biopsies. J Urol 2004; 171: 1419–1423.

    Article  Google Scholar 

  12. Mehrotra J, Varde S, Wang H, Chiu H, Vargo J, Gray K et al. Quantitative, spatial resolution of the epigenetic field effect in prostate cancer. Prostate 2008; 68: 152–160.

    Article  CAS  Google Scholar 

  13. Rizzi F, Belloni L, Crafa P, Lazzaretti M, Remondini D, Ferretti S et al. A novel gene signature for molecular diagnosis of human prostate cancer by RT-qPCR. PLoS ONE 2008; 3: e3617.

    Article  Google Scholar 

  14. Jonathan I, Epstein XJY . Findings of atypical glands suspicious for cancer. In: Prostate Biopsy Interpretation (3rd edn) Lippincott Williams & Wilkins: Philadelphia, pp 177–184.

  15. Dakubo GD, Jakupciak JP, Birch-Machin MA, Parr RL . Clinical implications and utility of field cancerization. Cancer Cell Int 2007; 7: 2.

    Article  Google Scholar 

  16. Haaland CM, Heaphy CM, Butler KS, Fischer EG, Griffith JK, Bisoffi M . Differential gene expression in tumor adjacent histologically normal prostatic tissue indicates field cancerization. Int J Oncol 2009; 35: 537–546.

    CAS  PubMed  Google Scholar 

  17. Theodorescu D, Frierson Jr HF, Sikes RA . Molecular determination of surgical margins using fossa biopsies at radical prostatectomy. J Urol 1999; 161: 1442–1448.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported in part by grants from Industry Canada (FedNor), Sudbury, Canada, and Northern Ontario Heritage Fund Corporations (NHOFC), Sault Ste Marie. We thank the patients and their physician for the samples.

Author information

Authors and Affiliations

  1. Genesis Genomics, Thunder Bay, ON, Canada

    K Robinson, J Creed, B Reguly, C Powell, R Wittock, D Klein, A Maggrah, R L Parr & G D Dakubo

  2. Division of Urology, Department of Surgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada

    L Klotz

Authors
  1. K Robinson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Creed
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B Reguly
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Powell
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R Wittock
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D Klein
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A Maggrah
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. L Klotz
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R L Parr
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. G D Dakubo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G D Dakubo.

Ethics declarations

Competing interests

The authors Kerry Robinson, Jennifer Creed, Brian Reguly, Cortney Powell, Roy Wittock, Daniel Klein, Andrea Maggrah, Ryan L. Parr and Gabriel D. Dakubo work for and own stocks in Genesis Genomics. Laurence Klotz is a paid consultant with Genesis Genomics.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Robinson, K., Creed, J., Reguly, B. et al. Accurate prediction of repeat prostate biopsy outcomes by a mitochondrial DNA deletion assay. Prostate Cancer Prostatic Dis 13, 126–131 (2010). https://doi.org/10.1038/pcan.2009.64

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2009.64

Keywords

This article is cited by

Search

Advanced search

Quick links